MBX Biosciences appoints Peter Radovich as independent director, board expands to eight
MBX Biosciences appointed Peter Radovich to its board of directors effective October 20, 2026, and the board set its size at eight directors. The filing says Mr. Radovich is independent under Nasdaq listing standards and will receive standard non-employee director compensation, including a stock option for 18,200 shares.
Key points
- Peter Radovich appointed director effective October 20, 2026, as a Class I director serving until the 2028 Annual Meeting of Stockholders
- Board size set at eight directors
- Initial non-qualified stock option to purchase 18,200 shares, granted on the appointment date, plus cash compensation under the non-employee director policy
- Company is entering into an indemnification agreement with Mr. Radovich in the same form as its other directors
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 22, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.